Day: March 29, 2026

PERTH, Australia, March 29, 2026 (GLOBE NEWSWIRE) — Alkane Resources Limited (ASX: ALK, TSX: ALK, OTCQX: ALKRY) (‘Alkane’) is pleased to announce that it has executed an A$110 million Revolving Credit Facility (“RCF”) and A$40 million Contingent Instrument Facility (“CIF”). Following the early repayment of the $45 million project finance facility in August 20251, and to provide additional flexibility, liquidity, and broaden banking relationships, Alkane executed an A$110 million RCF and A$40 million CIF under a syndicated facilities agreement with Australia and New Zealand Banking Group Limited, Commonwealth Bank of Australia, Macquarie Bank Limited and Westpac Banking Corporation. The RCF may be used for general corporate purposes. The CIF will allow cash used to back performance guarantees to be returned. Alkane is not required...

BEIJING, March 29, 2026 (GLOBE NEWSWIRE) — Autozi Internet Technology (Global) Ltd. (“Autozi” or the “Company”) (Nasdaq: AZI), one of China’s leading and fastest-growing lifecycle automotive service and supply-chain technology platforms, announced today that it has received a written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated March 25, 2026 indicating that the Company is not in compliance with the minimum Market Value of Listed Securities (“MVLS”) of US$50,000,000 set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq Global Market, as its MVLS for the 30 consecutive business days from February 10, 2026 to March 24, 2026 has failed to meet the minimum requirement. Pursuant to Nasdaq Listing Rule 5810(c)(3)(C), the Company has a compliance period of 180...

Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study1 40.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1 Fabhalta granted priority review by FDA for traditional approvalBasel, March 29, 2026 – Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA nephropathy (IgAN). Fabhalta demonstrated a statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope, a key marker of kidney function, compared with placebo1. Fabhalta consistently outperformed placebo across key kidney outcomes over two years, demonstrating a slowing of disease progression and the potential to preserve kidney function in IgAN1. The results were published in the New England...